Mitochondrial Blend blend

Last Updated: August 2026

The Mitochondrial Blend combines three research compounds that each touch cellular energy metabolism: 5-Amino-1MQ (an NNMT inhibitor studied for metabolic/fat effects), MOTS-c (a mitochondrial-derived peptide involved in metabolic regulation and insulin sensitivity), and NAD⁺ (the central cofactor for cellular energy and sirtuin activity). It is a research-use-only stack, not an approved combination product.

Why are these three combined?

The rationale is convergent: NAD⁺ replenishes the coenzyme that mitochondrial energy production and sirtuins depend on; in preclinical (mouse) studies MOTS-c improved metabolic homeostasis and insulin sensitivity; and 5-Amino-1MQ inhibits NNMT, an enzyme whose activity is linked to adipose expansion and lowered cellular NAD⁺/methylation capacity — so in principle the three reinforce a common "cellular energy / metabolic" theme. These are research directions, not proven combined outcomes.

What's the evidence and status?

Each component has its own (mostly preclinical or early) research base, but the combination has not been validated in controlled human trials as of August 2026 — it is an experiential/research stack, not an approved therapy. Treat efficacy claims about the blend cautiously and see each component's profile for its individual evidence. Always dose by the individual component amounts printed on your vial, never by a generic "blend dose" — and because composition varies by vendor, re-check them for every batch. Evidence level: Component-level, largely preclinical; blend not clinically validated.

What is the regulatory status of the Mitochondrial Blend's components?

None of the three components is approved by the FDA for human use as of August 2026. MOTS-c was among the peptides the FDA removed from its 503A Category 2 bulk-substances list in April 2026 after the nomination was withdrawn by the nominator — a removal that did not add it to Category 1 or authorise compounding. At its July 23–24, 2026 meeting the FDA's Pharmacy Compounding Advisory Committee voted to recommend MOTS-c (7–5–2) for the 503A compounding list — an advisory recommendation FDA reviewers opposed and the agency has not finalized; formal rulemaking is not expected before 2027. NAD⁺ is sold as a dietary-supplement ingredient rather than an approved drug, and 5-Amino-1MQ is a research-use-only compound with no regulatory approval anywhere. In sport, the two unapproved compounds (MOTS-c, 5-Amino-1MQ) fall under WADA's catch-all S0 category; NAD⁺ is not itself WADA-prohibited. Evidence level: regulatory status only — none FDA-approved; MOTS-c preclinical, NAD⁺ precursor RCTs show no clear functional benefit, 5-Amino-1MQ preclinical; the blend has no controlled human trial.

How does Peptigrity verify a three-part blend?

For a multi-compound stack, the checks are that each labeled component is present, correctly identified, and of adequate purity — HPLC and mass-spec across the components. Peptigrity collects independent third-party Certificates of Analysis for the 5-Amino-1MQ, MOTS-c and NAD⁺ components from shops' official channels and verifies each for authenticity before publishing; because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly, and a community-funded Testing Grant to purchase and test vials anonymously is in development. The trust score weights lab purity and reviews equally (50/50). Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. See how to read lab results.

Educational information only; not medical advice. This is a research-use-only stack, not an approved therapy. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.